Observes Nephoxil use for high phosphate in dialysis patients
Studies Nephoxil capsules for high phosphate in adults with chronic kidney disease on dialysis.
Plain-language title generated from the registry record
Registry title: Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule
Key facts
- Where
- Jeonju, South KoreaSee the site
Where in South Korea
- Jesus HospitalJeonju, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- LG Chem
- Trial code
- NCT06206135
- Record updated
- 3 September 2026
- Original description
The purpose of this study is to evaluate the safety and efficacy of Nephoxil capsule administration for the improvement of hyperphosphatemia in CKD patients undergoing hemodialysis under actual conditions of routine medical care.Read full original descriptionShow less
Multicenter, Open, Prospective, 48 Weeks, Observational Study in the Real-world to Evaluate the Safety and Efficacy of Nephoxil Capsule for Treatment of Hyperphosphatemia in Chronic Kidney Disease Patients on Dialysis
The purpose of this study is to evaluate the safety and efficacy of Nephoxil capsule administration for the improvement of hyperphosphatemia in CKD patients undergoing hemodialysis under actual conditions of routine medical care.
Inclusion: Adults 19 years of age or older as of the ICF date; CKD patients undergoing hemodialysis to whom Nephoxil capsule shall be administered for the first time for the treatment of hyperphosphatemia as per the determination of the investigator; Patients who voluntarily decide to participate in this study and complete the ICF.
Exclusion: Those who require concomitant administration of aluminum-containing medication; Those who fall under the "Do not administer to the following patients" criteria according to Nephoxil capsule indication approval; Others determined by the investigator to be unsuitable for participation in this study.